Why Investors Aren't Convinced on Bayer, Monsanto Deal

The transcript discusses concerns about Monsanto's potential financial demands in a corporate deal, highlighting investor worries about equity and debt. It also covers the CEO's bold decision to pursue the deal, emphasizing his strategic vision amidst industry shifts. The integration of the companies and regulatory challenges are also addressed, focusing on cost-cutting and the approval process.

What financial challenges might the buyer face in this deal?

What role do regulators play in the approval of this deal?